Biopolym. Cell. 2025; 41(3):155.
http://dx.doi.org/10.7124/bc.000B1F
Огляди
Інтерлейкіни та анти-інтерлейкінові аутоантитіла в нормі та при патології
1Лич І. В., 1Полунін А. О., 2Шкотова Л. В., 3Волошина І. М.
  1. Національний університет харчових технологій Вул. Володимирська, 68, Київ, Україна, 01601
  2. Інститут молекулярної біології і генетики НАН України
    Вул. Академіка Заболотного, 150, Київ, Україна, 03143
  3. Київський національний університет технологій та дизайну
    Вул. Мала Шияновська, 2, Київ, Україна, 01011

Abstract

Анти-інтерлейкінові аутоантитіла (АІА) – це особливий тип імуноглобулінів, які націлені проти власних інтерлейкінів (IL) організму, що є ключовими білковими медіаторами імунної системи. Попри те, що присутність АІА здебільшого асоціюється із рядом різних імунодефіцитних станів, останні дослідження демонструють, що їх наявність у здорових людей є варіантом норми, хоча і у невеликих кількостях. До того ж підвищення їх титрів може також бути маркером сприятливого прогнозу процесу або навіть зменшувати тяжкість перебігу деяких захворювань. Дослідження АІА відкриває нові перспективи для розуміння патогенезу аутоімунних і інфекційних захворювань, а також розроблення нових підходів ефективної та націленої терапії.
Keywords: інтерлейкіни, ревматоїдний артрит, анти-цитокінові аутоантитіла, анти-інтерлейкінові аутоантитіла, гострий респіраторний дистрес-синдром, астма, аутоімунний поліендокринний синдром 1го типу
Повний текст: (PDF, англійською)

References

[1] Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021; 8(15):e2004433.
[2] Knight V, Sepiashvili L. Cytokine testing and challenges for diagnostic and clinical monitoring use. J Allergy Clin Immunol. 2025; 155(2):410-3.
[3] Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018; 285(16):2944-71.
[4] Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. Trop Med Infect Dis. 2024; 9(1):13.
[5] Cavaillon JM. Pro- versus anti-inflammatory cytokines: myth or reality. Cell Mol Biol (Noisy-le-grand). 2001; 47(4):695-702.
[6] Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, Frei R, Garbani M, Globinska A, Hess L, Huitema C, Kubo T, Komlosi Z, Konieczna P, Kovacs N, Kucuksezer UC, Meyer N, Morita H, Olzhausen J, O'Mahony L, Pezer M, Prati M, Rebane A, Rhyner C, Rinaldi A, Sokolowska M, Stanic B, Sugita K, Treis A, van de Veen W, Wanke K, Wawrzyniak M, Wawrzyniak P, Wirz OF, Zakzuk JS, Akdis CA. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016; 138(4):984-1010.
[7] Evavold CL, Kagan JC. Diverse Control Mechanisms of the Interleukin-1 Cytokine Family. Front Cell Dev Biol. 2022; 10:910983.
[8] Zhang Y, Su J. Interleukin-2 family cytokines: An overview of genes, expression, signaling and functional roles in teleost. Dev Comp Immunol. 2023; 141:104645.
[9] Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity. 2019; 50(4):796-811.
[10] Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol. 2018; 10(2):a028415.
[11] Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol. 2019; 11(2):a028548.
[12] Mirlekar B, Pylayeva-Gupta Y. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers (Basel). 2021; 13(2):167.
[13] McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019; 50(4):892-906.
[14] Catalan-Dibene J, Vazquez MI, Luu VP, Nuccio SP, Karimzadeh A, Kastenschmidt JM, Villalta SA, Ushach I, Pone EJ, Casali P, Raffatellu M, Burkhardt AM, Hernandez-Ruiz M, Heller G, Hevezi PA, Zlotnik A. Identification of IL-40, a Novel B Cell-Associated Cytokine. J Immunol. 2017; 199(9):3326-35.
[15] Bridgewood C, Russell T, Weedon H, Baboolal T, Watad A, Sharif K, Cuthbert R, Wittmann M, Wechalekar M, McGonagle D. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol. 2019; 208:108253.
[16] Matsushima K, Yang D, Oppenheim JJ. Interleukin-8: An evolving chemokine. Cytokine. 2022; 153:155828.
[17] Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics. 2010; 5(1):30-55.
[18] Zhao R, Zhou H, Su SB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol. 2013; 17(3):658-69.
[19] Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021; 20(3):102763.
[20] Griffiths JS, Camilli G, Kotowicz NK, Ho J, Richardson JP, Naglik JR. Role for IL-1 Family Cytokines in Fungal Infections. Front Microbiol. 2021; 12:633047.
[21] Midiri A, Mancuso G, Beninati C, Gerace E, Biondo C. The Relevance of IL-1-Signaling in the Protection against Gram-Positive Bacteria. Pathogens. 2021; 10(2):132.
[22] Pinto SM, Subbannayya Y, Rex DAB, Raju R, Chatterjee O, Advani J, Radhakrishnan A, Keshava Prasad TS, Wani MR, Pandey A. A network map of IL-33 signaling pathway. J Cell Commun Signal. 2018; 12(3):615-24.
[23] Drake LY, Kita H. IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 2017; 278(1):173-84.
[24] Yuan C. IL-33 in autoimmunity; possible therapeutic target. Int Immunopharmacol. 2022; 108:108887.
[25] Piñeros AR, Campos LW, Fonseca DM, Bertolini TB, Gembre AF, Prado RQ, Alves-Filho JC, Ramos SG, Russo M, Bonato VL. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Sci Rep. 2017; 7(1):41240.
[26] Rostan O, Arshad MI, Piquet-Pellorce C, Robert-Gangneux F, Gangneux JP, Samson M. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun. 2015; 83(5):1738-48.
[27] Hsieh EW, Hernandez JD. Clean up by aisle 2: roles for IL-2 receptors in host defense and tolerance. Curr Opin Immunol. 2021; 72:298-308.
[28] Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020; 218:108515.
[29] Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018; 18(10):648-59.
[30] Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012; 13(10):925-31.
[31] Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 2021; 10:71.
[32] McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015; 75(1):38-50.
[33] May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015; 75(1):89-116.
[34] Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020; 16(6):335-45.
[35] Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 2022; 12:1023177.
[36] Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020; 28(5):115327.
[37] Shang L, Cao J, Zhao S, Zhang J, He Y. TYK2 in Immune Responses and Treatment of Psoriasis. J Inflamm Res. 2022; 15:5373-85.
[38] Verma R, Balakrishnan L, Sharma K, Khan AA, Advani J, Gowda H, Tripathy SP, Suar M, Pandey A, Gandotra S, Prasad TS, Shankar S. A network map of Interleukin-10 signaling pathway. J Cell Commun Signal. 2016; 10(1):61-7.
[39] Shih LJ, Yang CC, Liao MT, Lu KC, Hu WC, Lin CP. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. Virulence. 2023; 14(1):2190650.
[40] Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020; 217(1):e20190418.
[41] Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015; 33(1):747-85.
[42] Mizoguchi A, Yano A, Himuro H, Ezaki Y, Sadanaga T, Mizoguchi E. Clinical importance of IL-22 cascade in IBD. J Gastroenterol. 2018; 53(4):465-74.
[43] Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014; 25(4):415-21.
[44] Floss DM, Schröder J, Franke M, Scheller J. Insights into IL-23 biology: From structure to function. Cytokine Growth Factor Rev. 2015; 26(5):569-78.
[45] Ge Y, Huang M, Yao YM. Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis. Front Immunol. 2020; 11:1558.
[46] Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023; 20(3):217-51.
[47] Quiros-Roldan E, Sottini A, Signorini SG, Serana F, Tiecco G, Imberti L. Autoantibodies to Interferons in Infectious Diseases. Viruses. 2023; 15(5):1215.
[48] Jain D, Salunke DM. Antibody specificity and promiscuity. Biochem J. 2019; 476(3):433-47.
[49] Siloşi I, Siloşi CA, Boldeanu MV, Cojocaru M, Biciuşcă V, Avrămescu CS, Cojocaru IM, Bogdan M, FolcuŢi RM. The role of autoantibodies in health and disease. Rom J Morphol Embryol. 2016; 57(2 Suppl):633-8.
[50] Johnson D, Jiang W. Infectious diseases, autoantibodies, and autoimmunity. J Autoimmun. 2023; 137:102962.
[51] Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021; 20(2):102743.
[52] Amendt T, Jumaa H. Adaptive tolerance: Protection through self-recognition. Bioessays. 2022; 44(3):e2100236.
[53] Nicolò A, Amendt T, El Ayoubi O, Young M, Finzel S, Senel M, Voll RE, Jumaa H. Rheumatoid factor IgM autoantibodies control IgG homeostasis. Front Immunol. 2022; 13:1016263.
[54] Knight V. Immunodeficiency and Autoantibodies to Cytokines. J Appl Lab Med. 2022; 7(1):151-64.
[55] Feng A, Gonzalez MV, Kalaycioglu M, Yin X, Mumau M, Shyamsundar S, Bustamante MS, Chang SE, Dhingra S, Dodig-Crnkovic T, Schwenk JM, Garg T, Yoshizaki K, van Rhee F, Fajgenbaum DC, Utz PJ. Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients. Front Immunol. 2025; 16:1528465.
[56] Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, Kagamu H, Yoshizawa H, Keicho N, Goto H, Nakata K. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007; 581(10):2017-21.
[57] von Stemann JH, Rigas AS, Thørner LW, Rasmussen DGK, Pedersen OB, Rostgaard K, Erikstrup C, Ullum H, Hansen MB. Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8,972 healthy individuals: Results from the Danish Blood Donor Study. PLoS One. 2017; 12(6):e0179981.
[58] von Stemann JH, Dubois F, Saint-André V, Bondet V, Posseme C, Charbit B, Quintana-Murci L, Hansen MB, Ostrowski SR, Duffy D; Milieu Intérieur Consortium. Cytokine Autoantibodies Alter Gene Expression Profiles of Healthy Donors. Eur J Immunol. 2025; 55(1):e202451211.
[59] Merkel PA, Lebo T, Knight V. Functional Analysis of Anti-cytokine Autoantibodies Using Flow Cytometry. Front Immunol. 2019; 10:1517.
[60] Donadel N, Tesser A, Valencic E, De Martino E, Boz V, Pin A, Zorat F, Pozzato G, Tommasini A. An easy assay to detect autoantibodies neutralizing cytokines in subjects with critical infections. J Immunol Methods. 2024; 530:113696.
[61] Cortes-Acevedo P, Mendoza-Elvira SE, Döffinger R, Barcenas-Morales G. Secondary immunodeficiencies related to the presence of anti-cytokine autoantibodies. Gac Med Mex. 2023; 159(2):154-60.
[62] Ataya A, Knight V, Carey BC, Lee E, Tarling EJ, Wang T. The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review. Front Immunol. 2021; 12:752856.
[63] Shih HP, Ding JY, Yeh CF, Chi CY, Ku CL. Anti-interferon-γ autoantibody-associated immunodeficiency. Curr Opin Immunol. 2021; 72:206-14.
[64] Vincent T, Plawecki M, Goulabchand R, Guilpain P, Eliaou JF. Emerging clinical phenotypes associated with anti-cytokine autoantibodies. Autoimmun Rev. 2015; 14(6):528-35.
[65] Graudal NA, Svenson M, Tarp U, Garred P, Jurik AG, Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis. 2002; 61(7):598-602.
[66] Howe HS, Leung BPL. Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus. Cells. 2019; 9(1):72.
[67] Theut Riis P, von Stemann JH, Kjærsgaard Andersen R, Hansen MB, Jemec GBE. Serum Anticytokine Autoantibody Levels Are Not Increased in Hidradenitis Suppurativa: A Case-Control Pilot Study. Dermatology. 2017; 233(2-3):126-8.
[68] Carmona-Rivera C, O'Neil LJ, Patino-Martinez E, Shipman WD, Zhu C, Li QZ, Kerns ML, Barnes LA, Caffrey JA, Kang S, Kaplan MJ, Okoye GA, Byrd AS. Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages. J Invest Dermatol. 2022; 142(3 Pt B):924-35.
[69] Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat Commun. 2016; 7(1):13027.
[70] Bost KL, Hahn BH, Saag MS, Shaw GM, Weigent DA, Blalock JE. Individuals infected with HIV possess antibodies against IL-2. Immunology. 1988; 65(4):611-5.
[71] Shao M, Sun XL, Sun H, He J, Zhang RJ, Zhang X, Li ZG. Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus. Chin Med J (Engl). 2018; 131(13):1520-6.
[72] Cheng A, Holland SM. Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol. 2024; 24(3):161-77.
[73] Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, Mamani-Matsuda M, Jouanguy E, Gendrel D, Casanova JL. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008; 180(1):647-54.
[74] Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, Shirai T, Sugihara T, Hirata S, Kubota T, Harigai M, Miyasaka N. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann Rheum Dis. 2013; 72(6):1100-2.
[75] Bloomfield M, Parackova Z, Cabelova T, Pospisilova I, Kabicek P, Houstkova H, Sediva A. Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock. Front Immunol. 2019; 10:2629.
[76] Igarashi S, Ogawa T, Kushibiki T, Ito K, Matsukida A, Kato Y, Nagao K, Kawana A, Kimizuka Y. Fatal C-reactive Protein-less Sepsis with Anti-IL-6 Autoantibody Production after Administration of Durvalumab. Intern Med. 2025; 64(14):2213-7.
[77] Kärner J, Pihlap M, Ranki A, Krohn K, Trebusak Podkrajsek K, Bratanic N, Battelino T, Willcox N, Peterson P, Kisand K. IL-6-specific autoantibodies among APECED and thymoma patients. Immun Inflamm Dis. 2016; 4(2):235-43.
[78] Liu S, Zhang X, Wang J, Yang H, Jiang Y, Qiu C, Meng Q. Analysis of plasma autoantibodies for inflammatory cytokines in patients with first-episode schizophrenia among a Chinese population. J Neuroimmunol. 2020; 341:577165.
[79] Guo J, Ning XQ, Ding JY, Zheng YQ, Shi NN, Wu FY, Lin YK, Shih HP, Ting HT, Liang G, Lu XC, Kong JL, Wang K, Lu YB, Fu YJ, Hu R, Li TM, Pan KS, Li XY, Huang CY, Lo YF, Chang IY, Yeh CF, Tu KH, Tsai YH, Ku CL, Cao CW. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med. 2020; 217(12):e20190502.
[80] Fudala R, Krupa A, Matthay MA, Allen TC, Kurdowska AK. Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol. 2007; 293(2):L364-74.
[81] Kurdowska AK, Noble JM, Adcock JE. Interleukin-8 and anti-interleukin-8 autoantibodies in gingival crevicular fluid from patients with periodontitis. J Periodontal Res. 2003; 38(1):73-8.
[82] Peichl P, Pursch E, Bröll H, Lindley IJ. Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol Int. 1999; 18(4):141-5.
[83] Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol. 1993; 37(1):65-70.
[84] Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM, Gorelik E. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006; 102(2):244-51.
[85] Young Han C, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC Jr. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer. 2024; 130(5):861-8.
[86] Griffin H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, Davies S, Loo PS, Szabo A, Williams E, Mukhopadhyay A, McLoughlin L, Irwin S, Travis S, Klenerman P, Bunn S, Cant AJ, Hambleton S, Uhlig HH, Doffinger R. Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease. N Engl J Med. 2024; 391(5):434-41.
[87] Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachée-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougnères PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010; 207(2):291-7.
[88] Macias Robles AP, Cheng A, Holland SM, Lugo Reyes SO. Anti-IL12p40 autoantibodies in a teenage girl with multiple recurrent abscesses. Clin Immunol. 2024; 266:110335.
[89] Arts RJW, Janssen NAF, van de Veerdonk FL. Anticytokine Autoantibodies in Infectious Diseases: A Practical Overview. Int J Mol Sci. 2023; 25(1):515.
[90] Xie YL, Rosen LB, Sereti I, Barber DL, Chen RY, Hsu DC, Qasba SS, Zerbe CS, Holland SM, Browne SK. Severe Paradoxical Reaction During Treatment of Disseminated Tuberculosis in a Patient With Neutralizing Anti-IFNγ Autoantibodies. Clin Infect Dis. 2016; 62(6):770-3.
[91] Goda V, Malik A, Kalmar T, Maroti Z, Patel B, Ujhazi B, Csomos K, Hale JE, Chen K, Bleesing J, Palma P, Cancrini C, Comeau AM, Krivan G, Walter JE. Partial RAG deficiency in a patient with varicella infection, autoimmune cytopenia, and anticytokine antibodies. J Allergy Clin Immunol Pract. 2018; 6(5):1769-71.
[92] Sim BT, Browne SK, Vigliani M, Zachary D, Rosen L, Holland SM, Opal SM. Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies. J Clin Immunol. 2013; 33(6):1057-61.
[93] Cheng A, Kashyap A, Salvator H, Rosen LB, Colby D, Ardeshir-Larijani F, Loehrer PJ, Ding L, Lugo Reyes SO, Riminton S, Ballman M, Rocco JM, Marciano BE, Freeman AF, Browne SK, Hsu AP, Zelazny A, Rajan A, Sereti I, Zerbe CS, Lionakis MS, Holland SM. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. N Engl J Med. 2024; 390(12):1105-17.
[94] Wolff AS, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BE, Kisand K, Oláh E, Meloni A, Myhre AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol. 2013; 33(8):1341-8.
[95] Ji Y, Wang E, Mohammed MT, Hameed N, Christodoulou MI, Liu X, Zhou W, Fang Z, Jia N, Yu H, Zhou Z, Sun Y, Huang SK, McSharry C, Zhong NS, Xiao X, Li J, Xu D. Selective production of IL-33-neutralizing autoantibody ameliorates asthma responses and severity. Clin Immunol. 2024; 264:110234.
[96] Ritter K, Sodenkamp JC, Hölscher A, Behrends J, Hölscher C. IL-6 is not Absolutely Essential for the Development of a TH17 Immune Response after an Aerosol Infection with Mycobacterium Tuberculosis H37rv. Cells. 2020; 10(1):9.
[97] Cheng A, Holland SM. Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity. J Allergy Clin Immunol. 2022; 149(1):24-8.
[98] Duan S, Wang J, Lou X, Chen D, Shi P, Jiang H, Wang Z, Li W, Qian F. A novel anti-IL-33 antibody recognizes an epitope FVLHN of IL-33 and has a therapeutic effect on inflammatory diseases. Int Immunopharmacol. 2023; 122:110578.
[99] Hizawa N, Kawaguchi M, Huang SK, Nishimura M. Role of interleukin-17F in chronic inflammatory and allergic lung disease. Clin Exp Allergy. 2006; 36(9):1109-14.
[100] Jokinen M, Edelman S, Krohn K, Kankainen M, Ranki A. Neutralizing natural anti-IL-17F autoantibodies protect Autoimmune Polyendocrine Syndrome Type 1 (APS-1) patients from asthma. Clin Immunol. 2020; 219:108512.
[101] Hu Y, Feng Z, An G, Lv Z, Wang J, Cui Y, Corrigan CJ, Wang W, Li Q, Ying S. Edwardsiella tarda induces airways inflammation and production of autoantibodies against lung tissues through regulation of the IL-33-ST2 axis. Immunology. 2024; 173(3):575-89.
[102] Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. IL-33 stimulates CXCL8/IL-8 secretion in goblet cells but not normally differentiated airway cells. Clin Exp Allergy. 2014; 44(4):540-52.
[103] Ku CL, Chi CY, von Bernuth H, Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet. 2020; 139(6-7):783-94.